Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
A Prospective, multicenter, randomized controlled phase II study to evaluate the efficacy and safety of PD-L1 monoclonal antibody combined with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy and concurrent or delayed radiotherapy in patients with advanced HER2-negative breast cancer with brain metastasis
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 lat
- •Potwierdzony przerzutowy rak piersi z ujemnym HER2 i przerzutami do mózgu
- •Maksymalnie jedna wcześniejsza linia chemioterapii choroby przerzutowej
- •Przerzuty do mózgu niewymagające pilnego leczenia miejscowego
- •Co najmniej jedna mierzalna zmiana w mózgu
- •Wykluczone podejrzane przerzuty do opon mózgowo-rdzeniowych
- •Dobry stan sprawności (ECOG 0-1)
- •Dopuszczalne wcześniejsze leczenie antracykliną lub taksanem
- •Zgoda na antykoncepcję
- •Podpisana świadoma zgoda
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing 100021
Beijing, China
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.